KLH-Lymphoma Ig Vaccine
A chimeric lymphoma vaccine generated by combining the recipient's Ig idiotype (Id) protein with keyhole limpet hemocyanin (KLH), an immune stimulant, with potential antineoplastic activity. Vaccination with KLH-Lymphoma Ig Vaccine may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against lymphoma cells, resulting in decreased tumor growth. (NCI04) [ ]
Term info
KLH-Lymphoma Ig Vaccine
- Id KLH Lymphoma
- KLH-Lymphoma Ig Vaccine
- Lymphoma Ig Vaccine-KLH
NCIT_C128784
KLH-Lymphoma_Ig_Vaccine
659770
KLH-Lymphoma Ig Vaccine
Pharmacologic Substance, Immunologic Factor
C1517646
C2771
Term relations
- Anti-Idiotype Vaccine
- Chemical_Or_Drug_Has_Physiologic_Effect some T-Cell Activation
- Chemical_Or_Drug_Affects_Cell_Type_Or_Tissue some Cytotoxic T-Lymphocyte
- Chemical_Or_Drug_Affects_Abnormal_Cell some Neoplastic Lymphocyte
- Chemical_Or_Drug_Has_Mechanism_Of_Action some Antigen Sensitization
- Chemical_Or_Drug_Has_Physiologic_Effect some Immunopotentiation